Cardiol Therapeutics Inc Class A (CRDL) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.292x

Based on the latest financial reports, Cardiol Therapeutics Inc Class A (CRDL) has a cash flow conversion efficiency ratio of -0.292x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-5.23 Million ≈ $-3.78 Million USD) by net assets (CA$17.88 Million ≈ $12.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cardiol Therapeutics Inc Class A balance sheet independence to measure how much of total assets are equity-financed.

Cardiol Therapeutics Inc Class A - Cash Flow Conversion Efficiency Trend (2017–2025)

This chart illustrates how Cardiol Therapeutics Inc Class A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore CRDL operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.

Cardiol Therapeutics Inc Class A Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cardiol Therapeutics Inc Class A ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Atp Ticari Bilgisayar Agi ve Elektrik Guc Kaynaklari Uretim Pazarlama ve Ticaret IS:ATATP	-0.291x
Domo Inc NASDAQ:DOMO	-0.018x
Tonix Pharmaceuticals Holding Corp NASDAQ:TNXP	-0.162x
FENIX Resources Ltd AU:FEX	0.332x
Welldone Co TWO:6170	0.105x
Asara Resources Ltd AU:AS1	-0.027x
SAI SILKS (KALAMANDIR) LIMITED NSE:KALAMANDIR	0.143x
THE REJECT SHOP LTD F:RFD	N/A

Annual Cash Flow Conversion Efficiency for Cardiol Therapeutics Inc Class A (2017–2025)

The table below shows the annual cash flow conversion efficiency of Cardiol Therapeutics Inc Class A from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Cardiol Therapeutics Inc Class A market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CA$17.88 Million ≈ $12.93 Million	CA$-23.85 Million ≈ $-17.26 Million	-1.334x	-31.66%
2024-12-31	CA$24.73 Million ≈ $17.89 Million	CA$-25.06 Million ≈ $-18.13 Million	-1.013x	-13.68%
2023-12-31	CA$28.25 Million ≈ $20.43 Million	CA$-25.18 Million ≈ $-18.22 Million	-0.891x	-70.96%
2022-12-31	CA$52.20 Million ≈ $37.76 Million	CA$-27.22 Million ≈ $-19.69 Million	-0.521x	-68.80%
2021-12-31	CA$76.24 Million ≈ $55.15 Million	CA$-23.55 Million ≈ $-17.04 Million	-0.309x	+55.37%
2020-12-31	CA$13.27 Million ≈ $9.60 Million	CA$-9.19 Million ≈ $-6.64 Million	-0.692x	+10.76%
2019-12-31	CA$14.67 Million ≈ $10.61 Million	CA$-11.38 Million ≈ $-8.23 Million	-0.776x	-58.59%
2018-12-31	CA$22.27 Million ≈ $16.11 Million	CA$-10.89 Million ≈ $-7.88 Million	-0.489x	-8.02%
2017-12-31	CA$2.85 Million ≈ $2.06 Million	CA$-1.29 Million ≈ $-934.75K	-0.453x	--

About Cardiol Therapeutics Inc Class A

TO:CRDL Canada Drug Manufacturers - Specialty & Generic

Market Cap

$142.19 Million

CA$196.56 Million CAD

Market Cap Rank

#17794 Global

#572 in Canada

Share Price

CA$1.76

Change (1 day)

+2.92%

52-Week Range

CA$1.28 - CA$2.23

All Time High

CA$8.13